Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -89.1%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $502M | $38M | $134M | $103M | $216M | $449M | $225M | $773M | — | — | — |
| Enterprise Value | $649M | $185M | $350M | $620M | $478M | $900M | $721M | $694M | — | — | — |
| P/E Ratio → | -0.13 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.45 | 0.03 | 0.12 | 0.12 | 0.27 | 0.73 | 0.55 | 4.31 | — | — | — |
| P/B Ratio | 0.19 | 0.02 | 0.03 | 0.02 | 0.04 | 0.10 | 0.59 | 2.87 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 9.69 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.16 | 0.33 | 0.73 | 0.60 | 1.45 | 1.78 | 3.87 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.3% | 29.3% | 28.3% | 23.4% | 18.6% | 24.0% | 23.7% | 24.3% | 110.8% | 84.6% | 70.9% |
| Operating Margin | -277.9% | -277.9% | -22.1% | -218.4% | -97.1% | -25.8% | -25.7% | -77.5% | -33.7% | -6.8% | -12.9% |
| Net Profit Margin | -266.3% | -266.3% | -31.1% | -231.6% | -75.9% | -71.6% | -25.3% | -14.0% | 79.8% | 20.5% | 4.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -89.1% | -89.1% | -7.3% | -38.8% | -11.9% | -18.3% | -31.6% | -19.0% | — | 20.6% | 1.6% |
| ROA | -68.1% | -68.1% | -5.6% | -30.6% | -9.3% | -12.3% | -9.8% | -5.2% | 40.2% | 8.6% | 1.6% |
| ROIC | -66.2% | -66.2% | -3.6% | -25.5% | -10.7% | -4.1% | -14.6% | -84.7% | -16.4% | -3.4% | -6.5% |
| ROCE | -78.1% | -78.1% | -4.4% | -31.1% | -12.7% | -4.8% | -10.8% | -32.2% | -95.9% | -4.9% | -4.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.11 | 0.18 | 0.14 | 0.21 | 1.64 | 2.17 | — | 11.35 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 94.98 | — |
| Net Debt / Equity | — | 0.07 | 0.05 | 0.12 | 0.05 | 0.10 | 1.31 | -0.29 | — | 8.37 | -0.47 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 70.06 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -55.23 | -55.23 | -3.55 | -29.38 | -15.38 | -4.28 | -4.06 | -23.63 | -9.21 | -3.60 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.46 | 2.46 | 2.27 | 1.79 | 2.87 | 2.20 | 2.80 | 21.37 | 0.25 | 0.55 | 17.29 |
| Quick Ratio | 1.49 | 1.49 | 1.42 | 1.32 | 1.99 | 1.56 | 1.85 | 20.75 | 0.10 | 0.36 | 15.64 |
| Cash Ratio | 0.91 | 0.91 | 0.87 | 1.04 | 1.48 | 1.22 | 1.05 | 19.96 | 0.05 | 0.34 | 13.01 |
| Asset Turnover | — | 0.39 | 0.18 | 0.14 | 0.12 | 0.10 | 0.34 | 0.20 | 0.42 | 0.34 | 0.23 |
| Inventory Turnover | 2.14 | 2.14 | 2.24 | 2.39 | 2.08 | 1.84 | 2.64 | 6.15 | -0.33 | 0.42 | 1.18 |
| Days Sales Outstanding | — | 53.99 | 47.05 | 50.19 | 55.34 | 62.06 | 51.63 | 48.48 | 34.26 | 13.75 | 100.40 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.6% | 0.0% | 0.0% | 3.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 1.6% | 0.0% | 0.0% | 3.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $89M | $74M | $62M | $48M | $27M | $23M | $20M | $14M | $9M | $5M |
Persistent Operating Margin Deficits
Based on reported figures, Tilray's P/S ratio of 0.48 suggests the market is heavily discounting the company's diversified revenue streams, likely due to the persistent negative P/E of -0.14 and the ongoing uncertainty surrounding the integration of its disparate pharmaceutical and beverage business segments.
The current valuation appears to reflect a market skepticism toward the company's ability to achieve profitability, effectively pricing the stock as a distressed asset rather than a growth-oriented CPG entity. Investors should monitor whether the market continues to apply a conglomerate discount or if the beverage segment eventually warrants a standalone valuation multiple closer to traditional craft brewers.
As reported in recent financial statements, Tilray's ROIC has remained consistently negative, reaching -1.1% in 2026Q2, which indicates that the company is currently destroying shareholder value rather than compounding it through its aggressive horizontal expansion and capital-intensive infrastructure investments across multiple international jurisdictions.
The persistent inability to generate positive returns on invested capital suggests that the company's M&A-led growth strategy has failed to achieve the necessary scale to overcome its high fixed-cost base. This trend warrants further investigation into whether management can pivot toward organic efficiency or if the current asset base remains structurally incapable of delivering positive economic profit.
According to the latest quarterly data, Tilray's cash conversion cycle remains exceptionally high at 568 days in 2026Q2, a figure that highlights significant inefficiencies in managing inventory and receivables compared to broader industry standards for consumer packaged goods and pharmaceutical distribution entities.
The elevated days inventory outstanding, which reached 646 days in the most recent quarter, suggests a potential oversupply issue or a mismatch between production capacity and market demand. This inefficiency ties up critical liquidity and forces the company to rely on external financing, increasing the risk profile for shareholders during periods of market volatility.
Based on the company's reported figures, the current ratio of 2.81 provides a superficial appearance of liquidity, yet the quick ratio of 1.72, when adjusted for the high inventory levels, suggests that the company's ability to meet short-term obligations under stress remains vulnerable to persistent cash burn.
While the current ratio appears adequate, the reliance on inventory liquidation to satisfy short-term liabilities is a precarious position for a company operating in volatile regulatory environments. Investors should monitor the cash burn rate closely, as the current liquidity position may be insufficient to support long-term operations without further dilutive financing.
The P/S ratio is frequently misapplied to Tilray because it fails to account for the massive disparity in gross margins between the low-margin pharmaceutical distribution business and the higher-margin beverage alcohol segment, thereby obscuring the true quality of the company's consolidated revenue base.
Analysts should instead focus on a sum-of-the-parts valuation that separates the distribution business from the branded consumer segments to avoid overestimating the company's earning power. Relying on a consolidated P/S ratio ignores the structural drag of the distribution segment, which may lead to an inaccurate assessment of the company's long-term profitability potential.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TLRY stock.
Tilray Brands, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Tilray Brands, Inc.'s return on equity (ROE) is -89.1%. The historical average is -28.9%.
Based on historical data, Tilray Brands, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tilray Brands, Inc. has 29.3% gross margin and -277.9% operating margin.